Mirador Therapeutics
Lori Glenwinkel, PhD, is a highly experienced scientist specializing in computational biology and neurobiology research. With a strong background in genetics, genomics, and bioinformatics, Lori has worked in various academic and research institutions, including Columbia University and UC Berkeley. Currently, Lori holds the position of Scientist at Mirador Therapeutics, where Lori focuses on modeling human health metabolomics and genomics data to identify biomarkers. Throughout their career, Lori has contributed significantly to the field of biological sciences and continues to make significant advancements in their research.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.